Filtered By:
Condition: Sickle Cell Anemia
Management: Managed Care
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Sickle cell disease: current treatment and emerging therapies.
Abstract Sickle cell disease (SCD) is among the most common genetic diseases in the United States, affecting approximately 100,000 people. In the United States, SCD is characterized by a shortened life expectancy of only about 50 years in severe subtypes, significant quality-of-life impairments, and increased healthcare utilization and spending. SCD is characterized by chronic hemolytic anemia, vaso-occlusion, and progressive vascular injury affecting multiple organ systems. The pathophysiology is directly related to polymerization of deoxygenated hemoglobin, leading to a cascade of pathologic events including ery...
Source: The American Journal of Managed Care - October 31, 2019 Category: Health Management Authors: Neumayr LD, Hoppe CC, Brown C Tags: Am J Manag Care Source Type: research